Canis ISSN: 2398-2942

Fluoxetine hydrochloride

Synonym(s): For veterinary use - Reconcile®; For human use - Prozac®, Sarafem®, Ladose®, Fontex®

Contributor(s): Linda Horspool, Vetstream Ltd

Introduction

Name

  • IUPAC.

Class of drug

  • Antidepressant.
  • Selective serotonin re-uptake inhibitor (SSRI) class.

Description

Chemical name

  • (RS)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine

Molecular formula

  • C17H18F3NO-HCl

Molecular weight

  • 345.79

Physical properties

  • White to off-white crystalline solid.
  • Water Solubility: 14 mg/mL.
  • Octanol-water Partition Coefficient (log P, pH 7): 4.1.
  • Product as packaged for sale:
  • 8, 16, 32 and 64 mg tablets, in bottles containing 30 tablets - approved for veterinary use in dogs in the US.
  • 10 mg tablets - not approved for veterinary use.
  • 10, 20 and 40 mg tablets - not approved for veterinary use.
  • 4 mg/mL syrup - not approved for veterinary use.

Storage requirements

  • Veterinary product as packaged for sale:
    • Store at 20-25ºC (68-77ºF).
    • Excursions permitted between 15-30ºC (59-86ºF).
    • Do not remove desiccant canister from the bottle.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Treatment of canine separation anxiety Separation anxiety , in conjunction with a behavior modification plane:
    • Approved for use the US.
  • Treatment of aberrant compulsive behaviors Stereotype behavior , eg lick granulomas, self-mutilation, psychogenic pruritus/alopecia.
  • Dominance aggression in dogs Intraspecific intolerance.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Mixed function oxidase (cytochrome P450) inhibitor - administer with care with other agents undergoing hepatic metabolism. A washout period of 6 weeks may be required before commencing other treatment due to the long half-lives of fluoxetine and norfluoxetine.
  • Do not give in combination with a monoamine oxidase inhibitor (MAOI) for example, selegiline hydrochloride Selegiline hydrochloride (L-deprenyl) or amitraz Amitraz , or within a minimum of 14 days of discontinuing therapy with an MAOI.
  • Do not give concomitantly with drugs that lower the seizure threshold (eg phenothiazines such as acepromazine Acepromazine maleate or chlorpromazine).
  • Use with care concomitantly with aspirin Acetyl salicylic acid or other anticoagulants.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromVetMedResource and PubMed.
  • Fitzgerald KT, Bronstein AC (2013) Selective serotonin reuptake inhibitor exposure.Top Companion Anim Med 28,13-17 PubMed.
  • Thomas DE, Lee JA, Hovda LR (2012) Retrospective evaluation of toxicosis from selective serotonin reuptake inhibitor antidepressants: 313 dogs (2005-2010). J Vet Emerg Crit Care22, 674-681 PubMed.
  • Kukanich B, Kukanich KS, Rodriguez JR (2011) The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs.Vet Anaesth Analg 38(3), 224-230 PubMed.
  • Rosado B, García-Belenguer S, León M, Chacón G, Villegas A, Palacio J (2011) Effect of fluoxetine on blood concentrations of serotonin, cortisol and dehydroepiandrosterone in canine aggression. J Vet Pharmacol Ther 34(5), 430-436 PubMed.
  • Yalcin E (2010) Comparison of clomipramine and fluoxetine treatment of dogs with tail chasing. Tierarztl Prax Ausg K Kleintiere Heimtiere 38, 295-299 PubMed.
  • Irimajiri M, Luescher AU, Douglass G, Robertson-Plouch C, Zimmermann A, Hozak R (2009) Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs. J Am Vet Med Assoc 235, 705-709 PubMed.
  • Simpson BS, Landsberg GM, Reisner IR, Ciribassi JJ, Horwitz D, Houpt KA, Kroll TL, Luescher A, Moffat KS, Douglass G, Robertson-Plouch C, Veenhuizen MF, Zimmerman A, Clark TP (2007) Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther 8, 18-31 PubMed.
  • Jochle W (1998) Abnormal behaviors and adaptation problems in dogs and cats and their pharmacological control. Tierarztl Prax Ausg K Klientiere Heimtiere 26(6), 410-421.
  • Wynchbank D & Berk M (1998) Fluoxetine treatment of acral lick dermatitis in dogs - a placebo control randomised double blind trial. Depress Anxiety 8(1), 21-23.
  • Wynchank D & Berk M (1998b) Behavioral changes in dogs with acral lick dermatitis during a 2-month extension phase of fluoxetine treatment. Hum Psychopharmacol Clin Exp 13, 435-437.
  • Pohland R C & Bernhard N R (1997) Postmortem serum and tissue redistribution of fluoxetine and norfluoxetine in dogs following oral administration of fluoxetine hydrochloride (Prozac). J Forensic Sci 42(5), 812-816.
  • Rapaport J L, Ryland D H & Kriete M (1992) Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 49(7), 517-521.

Other sources of information


ADDED